John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated ...

Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab ...

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, ...

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and ...